Respiratory Distress Syndrome clinical trials at UC Irvine

3 in progress, 2 open to eligible people

Showing trials for

  • Add-on Reparixin in Adult Patients With ARDS

    open to eligible people ages 18 years and up

    Study objectives 1. To characterize the efficacy of reparixin in ameliorating lung injury and systemic inflammation and expediting clinical recovery and liberation from mechanical ventilation in adult patients with moderate to severe ARDS (PaO2/FIO2 ratio ≤ 200). 2. To evaluate the safety of reparixin vs. placebo in patients enrolled in the study.

    Orange, California and other locations

  • Extracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS)

    open to eligible people ages 18-75

    To evaluate the safety and efficacy of intravenous (IV) administration of bone marrow mesenchymal stem cell derived extracellular vesicles (EVs), ExoFlo, versus placebo for the treatment of hospitalized patients with moderate-to-severe Acute Respiratory Distress Syndrome (ARDS).

    Orange, California and other locations

  • Early Caffeine and LISA Compared to Caffeine and CPAP in Preterm Infants

    Sorry, in progress, not accepting new patients

    This study is being conducted to determine whether prophylactic administration of surfactant by the Less Invasive Surfactant Administration (LISA) method reduces the need for mechanical ventilation in the first 72 hours of life when compared to early Continuous Positive Airway Pressure (CPAP) alone.

    Irvine, California and other locations

Last updated: